Connor, Clark & Lunn Investment Management Ltd. Karuna Therapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$22 Billion
Q2 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$161.01 - $317.85 $1.67 Million - $3.31 Million	-10,401 Reduced 19.74%	42,289 $13.4 Million
Q3 2023 Nov 13, 2023	BUY	$164.66 - $218.08 $1.77 Million - $2.35 Million	10,779 Added 25.72%	52,690 $8.91 Million
Q2 2023 Aug 10, 2023	BUY	$176.32 - $240.22 $382,790 - $521,517	2,171 Added 5.46%	41,911 $9.09 Million
Q1 2023 May 09, 2023	BUY	$161.33 - $204.36 $660,485 - $836,649	4,094 Added 11.49%	39,740 $7.22 Million
Q4 2022 Feb 10, 2023	SELL	$191.53 - $236.82 $755,968 - $934,728	-3,947 Reduced 9.97%	35,646 $7 Million
Q3 2022 Nov 10, 2022	BUY	$123.79 - $277.42 $4.9 Million - $11 Million	39,593 New	39,593 $8.91 Million

Others Institutions Holding KRTX

# of Institutions

Shares Held

332K

Call Options Held

Put Options Held

View Full List

About Karuna Therapeutics, Inc.

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

More about KRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account